Samsung Bioepis and Celltrion are competing to become the first Korean company to develop a biosimilar to “Avastin,” a blockbustger drug for colorectal cancer developed by global pharmaceutical company Roche.The two companies previously competed over the development of a biosimilar to “Herceptin,” a